News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • InvestingPro flash sale offers full AI toolset for under $8/month.
  • Analyst recommends a measured long on Meta after Muse agent adoption and ad recovery.
  • Investors remain focused on Meta's large AI infrastructure spending that could weigh on shares.
  • Analyst calls Microsoft a buy, citing durable cloud and AI growth and reasonable P/E near 28.
  • Cewe Color launches up-to-€18m buyback, shares leap to 52-week intraday high.
  • European markets face DAX pressure from rising oil and caution ahead of the U.S. Fed decision.

Latest Articles

Trump Says Board of Peace Secures Deal for Hamas Disarmament in Gaza

Trump Says Board of Peace Secures Deal for Hamas Disarmament in Gaza

U.S. President Donald Trump announced that his so-called 'Board of Peace' has reached an agreement calling for the complete disarmament of Hamas and other armed groups in Gaza. The plan, described as a milestone in the implementation of the Trump 20-Point Plan, envisions phased disarmament, Israeli troop withdrawals, and an International Stabilizat…

Telix H1 2026 Results: Investor Webcast Notification

Telix H1 2026 Results: Investor Webcast Notification

Telix Pharmaceuticals Limited will release its financial results for the half-year ended June 30, 2026, on August 20, 2026, accompanied by an investor webcast and conference call. The company is a commercial-stage global radiopharmaceutical firm focused on targeted theranostics for cancer treatment and diagnosis, with an established prostate cancer…

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Replimune Group, Inc. announced a favorable outcome from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee regarding the Biologics License Application resubmission for RP1, an oncolytic immunotherapy, used in combination with nivolumab to treat advanced melanoma patients who progressed after prior anti-PD-1 therapy. The committee vo…

First Solar Pops After Q2 Results; Margins Reach Multi-Year Highs

First Solar Pops After Q2 Results; Margins Reach Multi-Year Highs

First Solar's shares climbed in after-hours trading after the company reported a major second-quarter earnings beat, with adjusted EPS of $3.92 versus a $3.01 consensus. Revenue matched estimates at $1.06 billion, while gross margin expanded to about 57%, aided by tariff-related provisions, advanced manufacturing tax credits and lower logistics cos…

MasTec Shares Plummet After Q2 Results Fail to Satisfy Elevated Expectations

MasTec Shares Plummet After Q2 Results Fail to Satisfy Elevated Expectations

MasTec Inc reported second-quarter 2026 results that were broadly in line with analyst forecasts but fell short of the lofty expectations baked into its stock. While revenue, adjusted EPS and backlog showed solid year-over-year gains, the company’s guidance raise and other developments did not quell profit-taking following a sizable run-up in the s…

DexCom Shares Jump After Q2 Beat, Margins Improve Sharply

DexCom Shares Jump After Q2 Beat, Margins Improve Sharply

DexCom's shares jumped 10.0% in after-hours trading after the continuous glucose monitoring company reported second-quarter 2026 results that topped analyst expectations across key metrics, including adjusted EPS of $0.70 and revenue of $1.31 billion. Gross margins and operating profit expanded materially, management left full-year revenue guidance…

AXT Shares Jump After Blowout Q2 and Multi-Year Indium Phosphide Deal

AXT Shares Jump After Blowout Q2 and Multi-Year Indium Phosphide Deal

AXT rallied sharply in after-hours trading following Q2 2026 results that far exceeded Wall Street forecasts, reporting $47.6 million in revenue and adjusted EPS of $0.19. The company also disclosed a capacity reservation agreement with Lumentum Operations for indium phosphide wafer substrates through the end of 2031, secured by two deposits totali…

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

Sanuwave Health, Inc., a NASDAQ-listed company specializing in FDA-approved wound care and regenerative medicine products, announced it will host a conference call on August 7, 2026, to discuss its Q2 2026 financial results. The company focuses on developing non-invasive medical systems for tissue repair and regeneration across various medical fiel…

Why I’m Shorting Intel into the AI Euphoria (A Tactical Trade Plan)

Why I’m Shorting Intel into the AI Euphoria (A Tactical Trade Plan)

Intel is enjoying real business momentum in Data Center & AI, but the stock's run and lofty valuation leave little margin for execution risk. This trade idea proposes a tactical short at $93.48 with a $65.00 target and $99.00 stop, sized for a mid-term window (45 trading days). The thesis rests on an earnings mix that still shows negative GAAP EPS,…